uniQure N.V. (NASDAQ:QURE) Insider Jeannette Potts Sells 4,670 Shares of Stock

uniQure N.V. (NASDAQ:QURE) insider Jeannette Potts sold 4,670 shares of the firm’s stock in a transaction on Monday, June 16th. The shares were sold at an average price of $15.14, for a total value of $70,703.80. Following the transaction, the insider now directly owns 115,073 shares of the company’s stock, valued at $1,742,205.22. This represents a 3.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

uniQure Stock Performance

Shares of QURE opened at $14.21 on Friday. The company has a quick ratio of 11.99, a current ratio of 11.99 and a debt-to-equity ratio of 1.53. The business’s 50 day moving average price is $14.20 and its 200-day moving average price is $13.84. uniQure N.V. has a 52 week low of $3.73 and a 52 week high of $19.18. The stock has a market cap of $778.42 million, a P/E ratio of -3.24 and a beta of 0.08.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.25. The business had revenue of $1.57 million for the quarter, compared to analysts’ expectations of $5.93 million. uniQure had a negative return on equity of 483.87% and a negative net margin of 1,077.05%. Equities research analysts anticipate that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on QURE. Cantor Fitzgerald raised uniQure to a “strong-buy” rating in a research report on Monday, May 19th. Chardan Capital reissued a “buy” rating and set a $38.00 price objective on shares of uniQure in a research report on Friday, May 30th. HC Wainwright reissued a “buy” rating and issued a $70.00 price target on shares of uniQure in a research report on Thursday, May 29th. Wall Street Zen cut uniQure from a “hold” rating to a “sell” rating in a research report on Saturday, June 14th. Finally, Guggenheim reissued a “buy” rating and issued a $28.00 price target on shares of uniQure in a research report on Monday, May 12th. One analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, uniQure currently has an average rating of “Moderate Buy” and an average price target of $37.82.

Hedge Funds Weigh In On uniQure

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Invesco Ltd. lifted its position in uniQure by 453.2% in the 4th quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company’s stock valued at $10,836,000 after acquiring an additional 502,684 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in uniQure in the 4th quarter valued at approximately $320,000. Assenagon Asset Management S.A. lifted its position in uniQure by 355.2% in the 1st quarter. Assenagon Asset Management S.A. now owns 334,894 shares of the biotechnology company’s stock valued at $3,550,000 after acquiring an additional 261,323 shares in the last quarter. Raymond James Financial Inc. bought a new position in uniQure in the 4th quarter valued at approximately $1,951,000. Finally, Northern Trust Corp lifted its position in uniQure by 2.1% in the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock valued at $1,688,000 after acquiring an additional 1,923 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.